Dynavax Technologies Inc. (NASDAQ: DVAX) stock surged by 8.07% at last close while the DVAX stock price rises by (5.24% in the pre-market trading session. Dynavax is a biopharmaceutical business in the commercial stage that is researching and monetizing new vaccines. HEPLISAV-B, the company’s first commercial medication, is licensed in the United States and the European Union for the treatment of hepatitis B virus infection generated by all known subtypes in people aged 18 and above.
>> 7 Top Picks for the Post-Pandemic Economy <<
DVAX stock’ Update
Dynavax Technologies and Medigen Vaccine Biologics which is a pharmaceutical firm specializing in the research and manufacture of vaccines and biologics have announced the launch of MVC-COV1901, a COVID-19 vaccine. This week, about 600,000 individuals are expected to receive the Medigen vaccination.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
MVC acquired Taiwan Emergency Use Authorization and clearance in July to include MVC-COV1901 in Taiwan’s COVID-19 vaccine vaccination program. MVC COVID-19 vaccine is recommended for people over the age of 20 and is given in two doses 28 days apart for COVID-19 protection. MVC shall provide a monthly safety management plan throughout the declared EUA period, and a vaccination efficacy report within one year of receiving EUA approval, according to the Advisory Committee.
Charles Chen, Chief Executive Officer at Medigen stated,
Medigen is grateful for the opportunity to assist the Taiwanese people and contribute to the worldwide response to the epidemic. They were thankful to the Taiwan FDA for granting emergency use authorization, and they appreciate the time and effort put in by both the TFDA personnel and the experts who attended the risk and benefit analysis conference. It’s encouraging to see a positive outcome from the Medigen team’s tireless efforts.
Ryan Spencer, Chief Executive Officer of DVAX stock stated,
They are delighted to announce that Medigen’s vaccination is now available to Taiwanese citizens. They’re really happy about this first EUA and approval for COVID-19 vaccines with CpG 1018 adjuvant, which they believe will be the start of many. They feel that adjuvanted vaccines can make a substantial contribution to current immunization efforts, given the limitations of existing vaccines and the worldwide vaccine deficit.